Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Leads BCW Index Decline

The BCW Index recorded a 1.42 percent drop this past week, as 12 of the 16 components lost ground. Leading the group of decliners was Bruker BioSciences, which fell 6.1 percent.

Molecular Devices led the four firms that reported gains for the tracking period ended Tuesday, with an increase of 5 percent. The firm reported its fourth-quarter 2005 results earlier today (see briefs).

For the week, the Dow Jones Industrial Average dropped 1.1 percent, the Nasdaq declined 2.3 percent, and the Nasdaq Biotech Index fell 1.3 percent.

BioCommerce Week Index of Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(Feb. 7, 2006)
Last Price
(Jan. 31, 2006)
% change
Agilent
A
34.01
33.91
0.29
Applied Biosystems
ABI
27.8
28.34
-1.91
Beckman
BEC
58.32
59.55
-2.07
Bio-Rad
BIO
65.68
67.4
-2.55
Bruker
BRKR
4.62
4.92
-6.10
Fisher Scientific
FSH
66.16
66.87
-1.06
GE
GE
32.31
32.75
-1.34
Harvard Bio
HBIO
4.62
4.78
-3.35
Invitrogen
IVGN
66.86
68.88
-2.93
Molecular Devices
MDCC
30.01
28.59
4.97
PerkinElmer
PKI
22.98
22.74
1.06
Qiagen
QGEN
12.2
11.84
3.04
Sigma
SIAL
63.53
64.88
-2.08
Stratagene
STGN
10.12
10.2
-0.78
Thermo
TMO
33.22
33.64
-1.25
Waters
WAT
40.53
41.95
-3.38
BCW Index Average
35.81
36.33
-1.42
The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.